<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00732693</url>
  </required_header>
  <id_info>
    <org_study_id>CLIC/Sargent-178000-R35464</org_study_id>
    <nct_id>NCT00732693</nct_id>
  </id_info>
  <brief_title>Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure</brief_title>
  <official_title>Comparison of Standard and Physiologic Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure and the Assessment of Skeletal, Cardiovascular and Reproductive Parameters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determine whether physiological sex steroid replacement improves
      parameters of skeletal, cardiovascular and reproductive health of women treated with current
      sex steroid replacement regimens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Premature ovarian failure, defined as the onset of the menopause before the age of 40 years,
      is a relatively common problem that affects 1% of women. There are a variety of aetiologies
      underlying premature ovarian failure including Turner syndrome and those with idiopathic
      onset, however with the increasing success of intensive treatment for childhood cancer, there
      are increasing numbers of young survivors, with a variety of late effects of treatment,
      including premature ovarian failure.

      Evidence is required for the optimal management of young women with premature ovarian
      failure, either as a result of childhood cancer treatment or for other reasons. These women
      are currently offered combined sex steroid replacement in the convenient form of the oral
      contraceptive pill, or hormone replacement therapy, designed for older women after the
      menopause. These preparations are not designed to achieve physiological replacement of
      oestrogen or progesterone, either in dosage or in biochemical structure - many preparations
      using synthetic derivatives. These younger women who have differing metabolic and
      psychological requirements are looking to a future of 30 or more years of replacement. The
      optimal mode of SSR is not known for young women with premature ovarian failure, however
      there is concern that current regimens may be inadequate for optimal skeletal and
      cardiovascular health.

      Current preliminary data demonstrates that use of physiological sex steroid replacement
      improves uterine parameters. Evidence is required to determine whether optimising sex steroid
      replacement can also significantly improve parameters of skeletal and cardiovascular health.
      Young women with ovarian failure face several decades of hormone replacement, so small
      improvements in management may make large differences to later morbidity and mortality.

      The aim of the study is to determine whether physiological sex steroid replacement improves
      parameters of skeletal, cardiovascular and reproductive health of women treated with current
      sex steroid replacement regimens.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 24 hour ambulatory blood pressure</measure>
    <time_frame>Before each washout period, then at 0, 3, 6 and 12 months of each treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone mineral density measurements (DEXA)</measure>
    <time_frame>Baseline, 14 and 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Uterine ultrasound scan to assess uterine volume, endometrial thickness, and uterine artery blood flow</measure>
    <time_frame>Before each washout period, then at 0, 3, 6 and 12 months of each treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central arterial blood pressure and arterial stiffness measured using peripheral arterial tonometry</measure>
    <time_frame>Before each washout period, then at 0, 3, 6 and 12 months of each treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical evidence of activity on the renin-angiotensin system, including plasma renin activity, angiotensin II, aldosterone, creatinine, urea and electrolyte concentrations.</measure>
    <time_frame>Before each washout period, then at 0, 3, 6 and 12 months of each treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum markers of collagen turnover and bone matrix formation</measure>
    <time_frame>Before each washout period, then at 0, 3, 6 and 12 months of each treatment phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormonal assays for gonadotrophins, FSH, LH and sex steroids estrogen and progesterone</measure>
    <time_frame>Before each washout period, then at 0, 3, 6 and 12 months of each treatment phase</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Premature Ovarian Failure</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with standard sex steroid replacement regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with physiologic sex steroid regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethinylestradiol / Norethisterone</intervention_name>
    <description>Oral ethinylestradiol 30mcg and norethisterone 1.5mg daily for weeks 1-3, followed by 7 &quot;pill free&quot; days</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Loestrin 30, Galen Ltd, UK</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol / Progesterone</intervention_name>
    <description>Transdermal estradiol 100mcg daily for week 1, then 150mcg daily for weeks 2-4; and vaginal progesterone pessaries 200mg twice daily for weeks 3-4</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Estraderm TTS, Novartis Pharmaceuticals UK Ltd</other_name>
    <other_name>Cyclogest, Activis UK Ltd</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premature Ovarian Failure

        Exclusion Criteria:

          -  Intercurrent illness
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>W Hamish B Wallace, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NHS Lothian / University of Edinburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH9 1LF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Bath LE, Critchley HO, Chambers SE, Anderson RA, Kelnar CJ, Wallace WH. Ovarian and uterine characteristics after total body irradiation in childhood and adolescence: response to sex steroid replacement. Br J Obstet Gynaecol. 1999 Dec;106(12):1265-72.</citation>
    <PMID>10609720</PMID>
  </reference>
  <reference>
    <citation>Critchley HO, Buckley CH, Anderson DC. Experience with a 'physiological' steroid replacement regimen for the establishment of a receptive endometrium in women with premature ovarian failure. Br J Obstet Gynaecol. 1990 Sep;97(9):804-10.</citation>
    <PMID>2242365</PMID>
  </reference>
  <reference>
    <citation>Critchley HO, Wallace WH, Shalet SM, Mamtora H, Higginson J, Anderson DC. Abdominal irradiation in childhood; the potential for pregnancy. Br J Obstet Gynaecol. 1992 May;99(5):392-4.</citation>
    <PMID>1622911</PMID>
  </reference>
  <reference>
    <citation>Davies MC, Gulekli B, Jacobs HS. Osteoporosis in Turner's syndrome and other forms of primary amenorrhoea. Clin Endocrinol (Oxf). 1995 Dec;43(6):741-6.</citation>
    <PMID>8736278</PMID>
  </reference>
  <reference>
    <citation>Hansen SW, Olsen N. Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: measurement of vasoconstrictor response to cold. J Clin Oncol. 1989 Jul;7(7):940-2.</citation>
    <PMID>2472472</PMID>
  </reference>
  <reference>
    <citation>Hawkins MM, Smith RA. Pregnancy outcomes in childhood cancer survivors: probable effects of abdominal irradiation. Int J Cancer. 1989 Mar 15;43(3):399-402.</citation>
    <PMID>2538400</PMID>
  </reference>
  <reference>
    <citation>Hoorweg-Nijman JJ, Kardos G, Roos JC, van Dijk HJ, Netelenbos C, Popp-Snijders C, de Ridder CM, Delemarre-van de Waal HA. Bone mineral density and markers of bone turnover in young adult survivors of childhood lymphoblastic leukaemia. Clin Endocrinol (Oxf). 1999 Feb;50(2):237-44.</citation>
    <PMID>10396368</PMID>
  </reference>
  <reference>
    <citation>Howell SJ, Shalet SM. Aetiology-specific effect of premature ovarian failure on bone mass - is residual ovarian function important? Clin Endocrinol (Oxf). 1999 Nov;51(5):531-4.</citation>
    <PMID>10594512</PMID>
  </reference>
  <reference>
    <citation>Kaneko N, Kawagoe S, Hiroi M. Turner's syndrome--review of the literature with reference to a successful pregnancy outcome. Gynecol Obstet Invest. 1990;29(2):81-7. Review.</citation>
    <PMID>2185981</PMID>
  </reference>
  <reference>
    <citation>Kr√∏lner B, Pors Nielsen S. Bone mineral content of the lumbar spine in normal and osteoporotic women: cross-sectional and longitudinal studies. Clin Sci (Lond). 1982 Mar;62(3):329-36.</citation>
    <PMID>6977427</PMID>
  </reference>
  <reference>
    <citation>Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999 Jun 10;340(23):1801-11. Review.</citation>
    <PMID>10362825</PMID>
  </reference>
  <reference>
    <citation>Register TC, Jayo MJ, Jerome CP. Oral contraceptive treatment inhibits the normal acquisition of bone mineral in skeletally immature young adult female monkeys. Osteoporos Int. 1997;7(4):348-53.</citation>
    <PMID>9373569</PMID>
  </reference>
  <reference>
    <citation>Rubin K. Turner syndrome and osteoporosis: mechanisms and prognosis. Pediatrics. 1998 Aug;102(2 Pt 3):481-5. Review.</citation>
    <PMID>9685448</PMID>
  </reference>
  <reference>
    <citation>Saenger P. Clinical review 48: The current status of diagnosis and therapeutic intervention in Turner's syndrome. J Clin Endocrinol Metab. 1993 Aug;77(2):297-301. Review.</citation>
    <PMID>8345029</PMID>
  </reference>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2008</study_first_submitted>
  <study_first_submitted_qc>August 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2008</study_first_posted>
  <last_update_submitted>August 11, 2008</last_update_submitted>
  <last_update_submitted_qc>August 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr W Hamish B Wallace, Consultant/Reader in Paediatric Oncology</name_title>
    <organization>NHS Lothian / University of Edinburgh</organization>
  </responsible_party>
  <keyword>Premature ovarian failure</keyword>
  <keyword>Sex hormone replacement</keyword>
  <keyword>HRT</keyword>
  <keyword>Blood pressure</keyword>
  <keyword>Bone mineral density</keyword>
  <keyword>Bone metabolism</keyword>
  <keyword>Uterine function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
    <mesh_term>Menopause, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Norethindrone acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

